0001562180-23-000253.txt : 20230105 0001562180-23-000253.hdr.sgml : 20230105 20230105202559 ACCESSION NUMBER: 0001562180-23-000253 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20230103 FILED AS OF DATE: 20230105 DATE AS OF CHANGE: 20230105 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Perry Andrew CENTRAL INDEX KEY: 0001877793 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38096 FILM NUMBER: 23513329 MAIL ADDRESS: STREET 1: C/O G1 THERAPEUTICS, INC. STREET 2: 700 PARK OFFICES DRIVE, SUITE 200 CITY: RESEARCH TRIANGLE PARK STATE: NC ZIP: 27709 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: G1 Therapeutics, Inc. CENTRAL INDEX KEY: 0001560241 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 263648180 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 700 PARK OFFICES DRIVE STREET 2: SUITE 200 CITY: RESEARCH TRIANGLE PARK STATE: NC ZIP: 27709 BUSINESS PHONE: 919-213-9835 MAIL ADDRESS: STREET 1: 700 PARK OFFICES DRIVE STREET 2: SUITE 200 CITY: RESEARCH TRIANGLE PARK STATE: NC ZIP: 27709 FORMER COMPANY: FORMER CONFORMED NAME: G-Zero Therapeutics, Inc. DATE OF NAME CHANGE: 20121012 4 1 primarydocument.xml PRIMARY DOCUMENT X0306 4 2023-01-03 false 0001560241 G1 Therapeutics, Inc. GTHX 0001877793 Perry Andrew 700 PARK OFFICES DRIVE, SUITE 200 RESEARCH TRIANGLE PARK NC 27709 false true false false Chief Commercial Officer Common Stock 2023-01-03 4 A false 16100.00 0.00 A 22120.00 D Common Stock 2023-01-04 4 S false 820.00 5.5756 D 21300.00 D Stock Options (Right to buy) 5.73 2023-01-03 4 A false 32100.00 0.00 A 2033-01-03 Common Stock 32100.00 32100.00 D Represents a restricted stock unit ("RSU") award that vests 25% on January 3, 2024 and 12.5% semi-annually thereafter, subject to the Reporting Person's continued service through each applicable vesting date. Each RSU represents a contingent right to receive one share of Issuer common stock. Represents (i) 20 shares of common stock; (ii) 6,000 RSUs from award granted on January 3, 2022; and (iii) 16,100 RSUs from award granted on January 3, 2023. The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell-to-cover" transaction and do not represent discretionary transactions by the Reporting Person. The price represents the weighted average price with a low of $5.44 and a high of $5.78. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Represents (i) 700 shares of common stock; (ii) 4,500 RSUs from award granted on January 3, 2022; and (iii) 16,100 RSUs from award granted on January 3, 2023. The shares underlying this option vest as to 25% of the shares on January 3, 2024, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date. Note: On January 3, 2023, the reporting person was also granted performance-based restricted stock units that are subject to material conditions beyond the reporting person's control, and, therefore, not considered derivative securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, and excluded from this report. /s/ James Stillman Hanson, attorney-in-fact 2023-01-05 EX-24 2 aperrypoa.txt POA POWER OF ATTORNEY Know all by these present, that the undersigned hereby constitutes and appoints each of James Stillman Hanson, General Counsel, of G1 Therapeutics, Inc. (the "Company"), Jennifer Moses, Chief Financial Officer of the Company, Sandi James, Director, Legal, of the Company, and Megan N. Gates, Raven Sun and Troy R. Nichols of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., signing singly, with full power of substitution, the undersigned's true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, forms and authentication documents for EDGAR Filing Access; (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such forms and authentication documents; (3) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer, director and/or 10% shareholder of the Company, Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder; (4) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4 or 5 and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and (5) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney- in-fact, may be of benefit to, in the best interests of, or legally required by the undersigned, it being understood that the documents executed by such attorney- in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion. The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended. This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys- in-fact. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed on August 6, 2021. /s/ Andrew Perry Signature Andrew Perry Print Name